New-onset migraine following closure of atrial septal defects in children

K. Armstrong,O. O’Mahony,L. Farah,D. Webb

DOI: https://doi.org/10.1177/0333102414523341

2014-10-01

Cephalalgia

Abstract:Dear Editor, We read with great interest the recent study by Kato et al. in which they report an increased incidence of migraine headaches following atrial septal defect (ASD) closure which is the largest cohort to date (1). We report four children who support their observation that younger patients (12–19 years) are at increased risk of migraine headache attacks. Three children in our series developed new-onset headache that were subsequently diagnosed as migraine within hours of ASD closure by Amplatzer device. The fourth child developed headaches within four weeks of ASD repair. The children were 3–14 years old and all received a diagnosis of migraine based on the International Headache Society Guidelines (2) (Table 1). Following Amplatzer device closure all three children were on aspirin prophylaxis for three months, and at two-year follow-up the migraines persisted. Rodés-Cabau et al. also observed new-onset migraine following ASD device closure in a small cohort of young patients aged 5–15 years. Their patients reported symptoms 2 to 30 days following ASD device closure (3). Causative theories for the nature of migraine headache attacks following ASD closure may be related to the formation of micro-emboli on the left atrial side during the endothelisation process with subsequent embolisation provoking migraine headache (4); however, this does not explain the persistent nature of the headaches in our case series. Other causative theories suggest a link between nickel release from the Amplatzer device chemically exacerbating the cortical spreading depression linked to migraine aura (5); however, there was no history of nickel allergy in our cases. Recognising that we report a small case series, we believe that it demonstrates a